Company news
Gain Therapeutics, Inc. (NASDAQ:GANX) news
Every Gain Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
August 25, 2026
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update
August 11, 2026
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
July 16, 2026
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
June 10, 2026
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026
May 26, 2026
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
May 11, 2026
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
April 24, 2026
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update
March 26, 2026
Gain Therapeutics to Present at the 38th Annual ROTH Conference
March 19, 2026
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Nove...
March 18, 2026
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update
March 12, 2026
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 19, 2026
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
January 7, 2026
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
January 6, 2026
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
December 18, 2025
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Park...
December 18, 2025
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025
November 20, 2025
Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update
November 12, 2025
Gain Therapeutics to Present at Neuroscience 2025
October 30, 2025
Gain Therapeutics to Attend the 2025 Maxim Growth Summit
October 16, 2025
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Par...
October 6, 2025
Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025
September 23, 2025
Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease
September 18, 2025
Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Re...
September 4, 2025
Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update
August 12, 2025
Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference
July 24, 2025
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering
July 16, 2025
Gain Therapeutics Announces Proposed Public Offering
July 15, 2025
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Dis...
June 30, 2025
Gain Therapeutics to Participate in Upcoming Investor Conferences
June 10, 2025
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
May 29, 2025
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update
May 14, 2025
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
May 12, 2025
Gain Therapeutics to Participate at The Citizens Life Sciences Conference
May 1, 2025
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
April 30, 2025
Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrol...
April 10, 2025
Gain Therapeutics Announces Poster Presentation at AD/PD 2025
March 28, 2025
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update
March 27, 2025
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease
March 14, 2025
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease
March 14, 2025
Gain Therapeutics Announces Oral Presentation at AD/PD 2025
March 6, 2025
Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287
January 8, 2025
Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director
January 7, 2025
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease
December 23, 2024
Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
November 14, 2024
Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identificatio...
October 23, 2024
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 15, 2024
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
October 7, 2024
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule ...
August 29, 2024
Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
August 8, 2024